Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Immunovant, Inc. entered into Purchase Agreement with Roivant Sciences, Ltd. valued at approximately $170,000,000 (effective 2023-09-26).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- Roivant Sciences, Ltd.
- Value
- approximately $170,000,000
- Effective
- 2023-09-26
Exact text from the filing
On September 26, 2023, the Company entered into a common stock purchase agreement (the “Purchase Agreement”) with Roivant Sciences, Ltd. (“RSL”).
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Immunovant, Inc. entered into Underwriting Agreement with Leerink Partners LLC, Piper Sandler & Co., Guggenheim Securities, LLC and Wells Fargo Securities, LLC, as representatives of the underwriters valued at approximately $280,060,000 (effective 2023-09-27).
- Action
- entry
- Agreement
- underwriting
- Counterparty
- Leerink Partners LLC, Piper Sandler & Co., Guggenheim Securities, LLC and Wells Fargo Securities, LLC, as representatives of the underwriters
- Value
- approximately $280,060,000
- Effective
- 2023-09-27
Exact text from the filing
On September 27, 2023, Immunovant, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC, Piper Sandler & Co., Guggenheim Securities, LLC and Wells Fargo Securities, LLC, as representatives (the “Representatives”) of the underwriters listed on Schedule A thereto, relating to the issuance and sale in an underwritten public offering (the “Public Offering”) by the Company of 7,370,000 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), at a public offering price of $38.00 per share.
View on SEC.gov